Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 daratumumab monotherapy in newly diagnosed stage 3B AL amyloidosis
NL-OMON54540Phase 2Completed
- Sponsor
- Stichting European Myeloma Network
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in light-chain amyloidosis, sponsored by Stichting European Myeloma Network. Primary endpoint: 6-month overall survival rate. Started Oct 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NL-OMON54540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54540.